SCHEMBL26694876

SCHEMBL26694876

COc1ccc(CN(Cc2ccc(OC)cc2)c2cc(Br)c(C(F)(F)F)nc2OC)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ MAPT P10636 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ CRHR1 P34998 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ QPCT Q16769 2/20 0.36
▸ FABP4 P15090 3/20 0.36
▸ TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30709767 1.00 CYP1A2 (0.38) CYP1A2CYP2C19CYP2C9MAPTLMNA
SCHEMBL27044015 0.82 LMNA (0.40) CYP1A2CYP2C19MAPTLMNAMEN1
SCHEMBL30709936 0.81 LMNA (0.39) CYP1A2CYP2C19MAPTLMNAMEN1
SCHEMBL26694586 0.81 LMNA (0.39) CYP1A2CYP2C19MAPTLMNAMEN1
SCHEMBL30731669 0.79 LMNA (0.39) CYP1A2CYP2C19MAPTLMNAMEN1
SCHEMBL27038859 0.79 LMNA (0.39) CYP1A2CYP2C19MAPTLMNAMEN1
SCHEMBL26694765 0.77 QPCT (0.42) CYP1A2CYP2C19MAPTLMNAKDM4E
SCHEMBL30710127 0.77 QPCT (0.42) CYP1A2CYP2C19MAPTLMNAKDM4E
SCHEMBL30709741 0.75 MEN1 (0.38) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL30709808 0.75 APLNR (0.37) CYP1A2CYP2C19MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2026-03-05 — — US disclosed
US-12338256-B2 Aza-tetracyclic oxazepine compounds and uses thereof GENENTECH, INC. (US) 2025-06-24 — — US disclosed
US-20240368186-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2024-11-07 — — US disclosed
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. 2024-01-25 — — US disclosed
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. 2024-01-25 — — US disclosed
WO-2023225302-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2023-11-23 — — WO disclosed
WO-2023225302-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2023-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12338256-B2 Aza-tetracyclic oxazepine compounds and uses thereof AZI2, TET3, OXA1L CYP1A2 1377/4885CYP2C19 1181/4885CYP2C9 2088/4885
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF AZI2, TET3, OXA1L CYP1A2 1377/4885CYP2C19 1181/4885CYP2C9 2088/4885
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF KRAS, NRAS, HRAS CYP1A2 1142/4885CYP2C19 1434/4885CYP2C9 1451/4885
US-20240368186-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF AZI2, TET3, OXA1L CYP1A2 1377/4885CYP2C19 1181/4885CYP2C9 2088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback